LifeMD Launches Novo Nordisk's Wegovy Pill Starting at $149 per Month
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
LifeMD (LFMD) announced it is now offering Novo Nordisk's (NVO) Wegovy pill, the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health, through its end-to-end telehealth platform. Eligible patients can access the Wegovy pill for as little as $149 per month, further expanding LifeMD's portfolio of branded obesity treatments, LifeMD said. This announcement broadens LifeMD's long-standing collaboration with Novo Nordisk.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LFMD with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LFMD
Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.400
Low
6.00
Averages
9.67
High
15.00
Current: 3.400
Low
6.00
Averages
9.67
High
15.00
About LFMD
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LifeMD Executives Allegedly Breached Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether LifeMD, Inc. executives breached their fiduciary duties to shareholders, with potential legal risks that could undermine shareholder confidence.
- Overstated Competitive Position: A federal securities lawsuit claims that LifeMD's competitive position was materially overstated, which may distort investor expectations regarding the company's future and impact shareholder investment decisions.
- Improper Financial Guidance: LifeMD's decision to raise its 2025 guidance is criticized as reckless due to the failure to adequately account for rising customer acquisition costs in its RexMD segment, potentially leading to poor future financial performance.
- Lack of Disclosure: The company failed to disclose customer acquisition costs related to the sale of obesity drugs, resulting in materially false and misleading statements about LifeMD's business, operations, and prospects, which could trigger shareholder lawsuits.
Continue Reading
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
Continue Reading